Hypoxia-inducible adenosine A2B receptor modulates proliferation of colon carcinoma cells

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Extracellular adenosine, acting via four receptor subtypes (A1, A2A, A2B, A3), influences numerous physiological processes.
• The specific roles of adenosine receptors in human cancer pathophysiology remain largely unexplored.
• Adenosine receptor A2B (ADORA2B) is implicated in various cellular functions, but its role in colorectal carcinogenesis requires further elucidation.

Purpose of the Study:

• To investigate the expression patterns of adenosine receptors in colorectal tissues and cancer cell lines.
• To determine the functional role of ADORA2B in colon cancer development and progression.
• To assess ADORA2B as a potential therapeutic target for colorectal cancer.

Main Methods:

• Reverse transcriptase polymerase chain reaction (RT-PCR) and Western blotting were used to assess ADORA2B expression.
• Immunohistochemistry was employed to evaluate ADORA2B protein localization and prevalence in colorectal tissues.
• Cell proliferation assays (MTT) were conducted using an ADORA2B-selective antagonist (MRS1754) under normoxic and hypoxic conditions.

Main Results:

• ADORA2B was significantly upregulated in colorectal carcinoma tissues and cell lines compared to normal mucosa.
• Immunohistochemistry revealed ADORA2B positivity in 67% of adenocarcinomas and 17% of tubular adenomas, but not in normal glands.
• Hypoxia induced significant increases in ADORA2B mRNA and protein levels in colon cancer cell lines.
• Treatment with the ADORA2B antagonist MRS1754 dose-dependently inhibited colon carcinoma cell growth.

Conclusions:

• ADORA2B is overexpressed in colorectal carcinomas, particularly under hypoxic conditions, suggesting a role in promoting tumor growth.
• The findings indicate that ADORA2B plays a significant role in colon carcinogenesis.
• ADORA2B represents a promising therapeutic target for the treatment of colorectal cancer.